References
- Centers for Disease Control and Prevention, Department of Health and Human Services. Diabetes data and trends. National Diabetes Fact Sheet 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed July 2009
- American Diabetes Association (ADA). Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31:1–20
- Narayan KMV, Boyle JP, Geiss LS, Impact of recent increase in incidence on future diabetes burden. US, 2005–2050. Diabetes Care 2006;29:2114–2116
- American Diabetes Association (ADA). Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917–932
- Nathan DM, Buse JB, Ferrannini E, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
- Holman RR, Paul SK, Bethel MA, Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565–1576
- Leichter S. Is the use of insulin analogues cost-effective? Adv Ther 2008;25:285–299
- Bretzel RG, Arnolds S, Medding J, A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 2004;27:1023–1027
- Poulsen MK, Henriksen JE, Hother-nielsen O, The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003;26:3273–3279
- Perriello G, Pampanelli S, Porcellati F, Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double–blind and cross-over trial. Diabet Med 2005;22:606–611
- Liebl A, Prager R, Binz K, Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45–52
- Palmer JL, Goodall G, Nielsen S, Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin 2008;24:1417–1428
- Ray JA, Valentine WJ, Roze S, Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metab 2007;9:103–113